Neogenix Oncology
Neogenix Oncology develops novel therapeutic and diagnostic products for the treatment of cancer patients
About Neogenix Oncology
Neogenix Oncology, Inc. was a clinical-stage biotechnology company founded in 2003 by Dr. Myron Arlen. The firm was established to build upon the pioneering immunotherapy work of Dr. Arlen and his collaborator, Dr. Ariel Hollinshead, who had isolated various tumor-associated antigens (TAAs) in the 1970s and 1980s. Dr. Arlen, a surgical oncologist at Memorial Sloan-Kettering and North Shore University Hospital, recognized the untapped potential of Dr. Hollinshead's library of cancer vaccines, which had shown promise in early clinical trials but could not be fully analyzed with the technology of that era.
The company focused on developing therapeutic and diagnostic antibodies for the treatment of various cancers, including pancreatic, colorectal, lung, and prostate cancer. Its business model centered on advancing a pipeline of monoclonal antibodies (mAbs) and their corresponding companion diagnostics. In 2004, Neogenix acquired sole ownership of the Hollinshead library of vaccines, antibodies, and antigens. The company's lead candidate, NEO-101 (Ensituximab), was a monoclonal antibody that entered Phase IIa trials for colorectal and pancreatic cancer. Other candidates, NEO-201 and NEO-301, were in the preclinical stage. To support its clinical programs, Neogenix formed partnerships, such as an agreement with Cambridge Biomedical, Inc. in 2011 to develop diagnostic serum ELISA assays.
Over its operational history, Neogenix Oncology raised a total of $15.8 million in funding over two rounds. Despite its efforts, the company faced financial challenges. In June 2012, it entered into a non-binding letter of intent with Precision Biologics, Inc., a corporation funded by several Neogenix shareholders, for the acquisition of its assets through a Chapter 11 bankruptcy proceeding. The following month, an asset purchase agreement was signed, and in September 2012, Precision Biologics officially acquired Neogenix's library of vaccines, antibodies, antigens, and other assets. Following the acquisition, Neogenix Oncology was classified as an acqui-hired, deadpooled company.
Source: Dealroom company dataNews
Open roles
Neogenix Oncology in the Town of North Hempstead ecosystem
The Neogenix Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neogenix Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neogenix Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


